MA47370A - Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines - Google Patents

Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines

Info

Publication number
MA47370A
MA47370A MA047370A MA47370A MA47370A MA 47370 A MA47370 A MA 47370A MA 047370 A MA047370 A MA 047370A MA 47370 A MA47370 A MA 47370A MA 47370 A MA47370 A MA 47370A
Authority
MA
Morocco
Prior art keywords
heteraryl
modulators
bis
derivatives
protein aggregation
Prior art date
Application number
MA047370A
Other languages
English (en)
Inventor
Adrian Hall
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA47370A publication Critical patent/MA47370A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047370A 2017-01-26 2018-01-23 Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines MA47370A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17153214 2017-01-26

Publications (1)

Publication Number Publication Date
MA47370A true MA47370A (fr) 2021-03-24

Family

ID=57906527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047370A MA47370A (fr) 2017-01-26 2018-01-23 Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines

Country Status (17)

Country Link
US (1) US10913735B2 (fr)
EP (1) EP3573982B1 (fr)
JP (1) JP7100043B2 (fr)
KR (1) KR20190111080A (fr)
CN (1) CN110198938B (fr)
AU (1) AU2018212436A1 (fr)
BR (1) BR112019011932A2 (fr)
CA (1) CA3048947A1 (fr)
CL (1) CL2019001752A1 (fr)
CO (1) CO2019007835A2 (fr)
EA (1) EA201991756A1 (fr)
ES (1) ES2882285T3 (fr)
IL (1) IL267994A (fr)
MA (1) MA47370A (fr)
MX (1) MX2019007053A (fr)
RU (1) RU2019126170A (fr)
WO (1) WO2018138086A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009896A (es) 2014-01-29 2017-01-11 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina.
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
JP7100042B2 (ja) * 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのアルコキシビス-ヘテロアリール誘導体
EP3573986B1 (fr) 2017-01-26 2021-05-26 UCB Biopharma SRL Dérivés bis-hétéroaryliques bicycliques en tant que modulateurs de l'agrégation protéinique
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
WO2023125376A1 (fr) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 Composé hétéroarylamide bicyclique fusionné utile en tant qu'inhibiteur de l'agrégation de protéines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CN102725284A (zh) 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (fr) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Procédés et composés pouvant être utilisés pour traiter les maladies neurodégénératives
RU2014143242A (ru) 2012-03-28 2016-05-20 Ньюропор Терапис, Инк. Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка
US9284309B2 (en) * 2012-07-16 2016-03-15 Neuropore Therapies, Inc. Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation
MX2016009896A (es) * 2014-01-29 2017-01-11 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina.
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
JP7100042B2 (ja) 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのアルコキシビス-ヘテロアリール誘導体
EP3573986B1 (fr) 2017-01-26 2021-05-26 UCB Biopharma SRL Dérivés bis-hétéroaryliques bicycliques en tant que modulateurs de l'agrégation protéinique

Also Published As

Publication number Publication date
CA3048947A1 (fr) 2018-08-02
US20190367502A1 (en) 2019-12-05
CN110198938A (zh) 2019-09-03
JP2020505372A (ja) 2020-02-20
BR112019011932A2 (pt) 2019-10-29
CL2019001752A1 (es) 2019-11-22
WO2018138086A1 (fr) 2018-08-02
CO2019007835A2 (es) 2019-07-31
EP3573982A1 (fr) 2019-12-04
JP7100043B2 (ja) 2022-07-12
AU2018212436A1 (en) 2019-07-25
US10913735B2 (en) 2021-02-09
ES2882285T3 (es) 2021-12-01
MX2019007053A (es) 2019-08-29
IL267994A (en) 2019-09-26
EP3573982B1 (fr) 2021-06-16
KR20190111080A (ko) 2019-10-01
RU2019126170A (ru) 2021-02-26
CN110198938B (zh) 2023-03-14
EA201991756A1 (ru) 2020-01-23

Similar Documents

Publication Publication Date Title
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA44075A (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA42810A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA43251A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
EA201790785A1 (ru) Производные тетрагидроизохинолина
MA49126A (fr) Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
MA51133A (fr) Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc
EA201991855A1 (ru) Амин- или (тио)амидсодержащие модуляторы печеночных x-рецепторов (lxr)
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
MA45552A (fr) Compositions destinées au traitement de l'amylose